Short answer
Bicara Therapeutics Inc. (BCAX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$71M
- −96.1% YoY · −28.5% QoQ
- EPS (diluted)
- −$1.05
- −59.1% YoY · −31.3% QoQ
Source: XBRL data from the Bicara Therapeutics Inc. (BCAX) Q3 2026 10-Q on SEC EDGAR. USD.
Bicara Therapeutics Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales or other revenue generated
- Net loss $71.2M vs $36.3M YoY, operating expenses $75.7M vs $40.7M
- R&D highest spending area: $56.5M vs $33.0M, driven by FORTIFI-HN01 and FORTIFI-FLEX
- Cash, equivalents and marketable securities $442.3M; operating cash use $137.8M vs $82.9M
- February offering added $161.8M; funding expected into first half of 2029, additional capital needed thereafter
Risk Factors
- No explicit new risk factor identified versus the 10-K; filing presents existing risks without a change statement
- Financial: $442.3 million cash, equivalents and marketable securities projected to fund operations into first half of 2029
- Regulatory: BIOSECURE Act restrictions could impair supply from Chinese biotechnology partners, with prohibitions expected in 2027 at earliest
- Operational: Reliance on WuXi Biologics for ongoing clinical supply creates concentration risk amid China-U.S. geopolitical tensions
- Clinical: Ficerafusp alfa’s Phase 2/3 FORTIFI-HN01 trial faces enrollment, safety and regulatory approval uncertainty
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bicara Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.